Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.
View Top Employees from Pinteon Therapeutics| Website | http://www.pinteon.com |
| Revenue | $1 million |
| Employees | 7 (1 on RocketReach) |
| Founded | 2014 |
| Address | 1188 Centre St, Newton Center, Massachusetts 02459, US |
| Phone | (917) 607-0015 |
| Industry | Biotechnology Research, Business Services General, Health Care, Drug Delivery, Business Services, Medical, Pharmaceuticals, Therapeutics |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular Pinteon Therapeutics employee's phone or email?
Pinteon Therapeutics Questions
The Pinteon Therapeutics annual revenue was $1 million in 2024.
Michael Ahlijanian is the Chief Scientific Officer of Pinteon Therapeutics.
1 people are employed at Pinteon Therapeutics.
Pinteon Therapeutics is based in Newton Center, Massachusetts.
The NAICS codes for Pinteon Therapeutics are [54, 54171, 541714, 541, 5417].
The SIC codes for Pinteon Therapeutics are [873, 87].
Top Pinteon Therapeutics Employees
Related Companies
